Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Indevus gets approvable letter
Indevus got a preliminary FDA nod on Valstar, its bladder cancer therapy. The drug had been taken off the market in 2002 because of "impurities" in the original formula; since then, the company has revamped its process. In May, Indevus submitted a chemistry, manufacturing, and controls supplement to the agency.
The FDA's new approvable letter blesses the chemistry portion of the app and asks for more info about manufacturing. Company officials say they'll answer within two months, and that they expect to re-introduce VALSTAR late this year or early next.Â
- check out the release
Related Articles:
Indevus in $120M deal to acquire Valera. Report
Indevus halts research on pagoclone for PE. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
